Navigation Links
Studies in animals suggest 2009 H1N1 virus may have biological advantage over seasonal influenza
Date:9/1/2009

Preliminary findings in ferrets suggest that the novel 2009 H1N1 influenza virus may outcompete human seasonal influenza viruses, researchers say. Tests in animals showed that levels of the 2009 H1N1 virus rose more quickly than levels of the seasonal virus strains, and the new virus caused more severe disease. In line with previous findings by other research groups, the University of Maryland researchers also observed that the novel H1N1 virus was transmitted more easily from infected to uninfected ferrets than either of the two seasonal influenza viruses.

The researchers found no evidence that the 2009 H1N1 virus combined with either of two seasonal flu viruses to form new, so-called reassortant viruses. These findings suggest that while 2009 H1N1 virus probably will predominate in the coming flu season, there may not be biological pressure for the new virus to re-combine with other circulating viruses, the researchers say.

The work was done by Daniel Perez, Ph.D., and colleagues from the University of Maryland. The researchers were supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

"This elegant study, conducted in a useful animal model of human influenza, provides important information about how the 2009 H1N1 influenza virus interacts with other flu virus strains," says NIAID Director Anthony S. Fauci, M.D. "The results suggest that 2009 H1N1 influenza may outcompete seasonal flu virus strains and may be more communicable as well. These new data, while preliminary, underscore the need for vaccinating against both seasonal influenza and the 2009 H1N1 influenza this fall and winter."

When the investigators inoculated ferrets with 2009 H1N1 virus plus either seasonal H1N1 virus or seasonal H3N2 virus, the animals became co-infected with both viruses. However, only the 2009 H1N1 virus was then transmitted from co-infected ferrets to uninfected ferrets; there was no evidence that either of the seasonal flu viruses were transmitted between co-infected and uninfected animals. "The H1N1 pandemic virus has a clear biological advantage over the two main seasonal flu strains and all the makings of a virus fully adapted to humans," says Dr. Perez.

Next, the team conducted experiments to learn whether 2009 H1N1 virus would combine with seasonal flu viruses in co-infected animals to create new reassortant viruses. Some scientists have speculated that reassortant viruses may be more virulent or transmissible than either 2009 H1N1 or seasonal flu viruses alone. The researchers collected virus-containing material from the ferrets' nasal cavities, but found no evidence of reassortment between the 2009 H1N1 and seasonal influenza strains, either in ferrets that were directly infected with both viruses or in ferrets that came in contact with the co-infected animals.


'/>"/>

Contact: Anne A. Oplinger
aoplinger@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Related medicine news :

1. Gene Studies of Male-Female Differences Often Flawed
2. Two studies published in the Lancet
3. Study of Studies Finds No Risk to Children From Phthalates in Toys
4. Just Completed Studies Reveal Impact of New Medicare Reimbursement Regulations
5. Studies Prove Exercise Can Heal the Body Mind and Soul
6. Studies Shed New Light on Breast Cancer, Treatment
7. Multi-Year Compendium of Pharmaceutical Case Studies Available from Best Practices, LLC
8. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
9. Best Practice Database: Complimentary Excerpt of Three Sales Force Excellence Studies
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. NIH awards Einstein multimillion dollar grant to extend studies of exceptional longevity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... , ... Kevin Harrington (one of the original Sharks from mega-hit reality series ... topic of Beauty and Personal Care. , Everyone makes New Year’s ... commit to these changes than beginning with personal care and beauty products? AsSeenOnTV.pro will ...
(Date:1/17/2017)... TX (PRWEB) , ... January 17, 2017 , ... Mirror ... have earned the highest honor of Diamond Level in Zeltiq’s Crystal Rewards Program. Practice ... named part of this elite group of providers. , Produced by Zeltiq, CoolSculpting ...
(Date:1/17/2017)... ... January 17, 2017 , ... A prescription medication bottle, ... the fourth Cradle to Cradle Product Design Challenge , the Cradle to ... series of six circular design challenges scheduled to run through early 2018. The challenges ...
(Date:1/17/2017)... ... ... SC&H Group, a leading audit, tax, and consulting firm, announced that Chris ... practice . Rossi is the third technology consulting leader to join SC&H Group’s IT ... the practice continues to expand.     , Bringing more than 25 years of business consulting ...
(Date:1/17/2017)... ... January 17, 2017 , ... The Sharie Withers Agency, a ... the latest beneficiary of their thriving community involvement program. The current campaign fundraises ... the dreams of terminally ill patients. Donations to this worthy cause may now ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... , Jan 17, 2017 Research and ... Devices System Market 2016-2020" report to their offering. ... The global artificial pancreas ... the period 2016-2020. Global Artificial Pancreas Devices System Market ... inputs from industry experts. The report covers the market landscape and ...
(Date:1/17/2017)... , Jan. 17, 2017 The interventional ... billion by 2021 from USD 6.35 billion in 2016, ... driving the growth of this market are rising incidence ... for minimally invasive surgeries. The global interventional ... application, and region. On the basis of type, the ...
(Date:1/17/2017)... 2017 Management to Discuss Acquisition of ... KIT-302 Development On Track For An NDA ... in Q1 2017   ... Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV ; TASE: KTOV), an innovative biopharmaceutical ... 23 rd at 8:30am Eastern Time to discuss the recent acquisition of ...
Breaking Medicine Technology: